Centro Regionale | |
Direttore della struttura | Prof. Pierangelo Geppetti |
Prof. Federigo Sicuteri |
Prof. Chiarugi Alberto Dr. De Cesaris Francesco Dr. Iannone Luigi Francesco |
|
Altri componenti della struttura |
Dr. Andrea Burgalassi - Medico Dr. Giulia Vigani |
Monday | 11:00 - 14:00 | |
Tuesday | 11:00 - 14:00 | |
Wednesday | 11:00 - 14:00 | |
Thursday | 11:00 - 14:00 | |
Friday | 11:00 - 14:00 |
Monday | 08:00 - 18:00 | |
Tuesday | 08:00 - 18:00 | |
Wednesday | 08:00 - 18:00 | |
Thursday | 08:00 - 18:00 | |
Friday | 08:00 - 18:00 |
Monday | 08:00 - 18:00 | |
Tuesday | 08:00 - 16:30 | |
Wednesday | 08:00 - 16:30 | |
Thursday | 08:00 - 18:00 | |
Friday | 08:00 - 16:30 |
Visita specialistica Visita di controllo Test farmacologici Test genetici Disassuefazione dagli analgesici Attività informativa per il paziente Altro: Prescrizione e somministrazione di tossina botulinica tipo A, Prescrizione e somministrazione anticorpi anti-CGRP |
|
NO |
1200 | |
890 | |
NO | |
NO | |
Tossina botulinica Altro: Somministrazione anticorpi monoclonali anti-CGRP |
SI | |
SI | |
SI | |
SI | |
SI |
Titolo protocollo | Nome del comitato etico | Numero di riferimento |
---|---|---|
Registro Italiano delle Cefalee (RiCe) | ||
Phase 4 A REAL-world, retrospective cohort study of the prevention of episodic or chronic migraine in patients treated with galcanezumab at headache centres in ITalY: REALITY | ||
Phase 4 Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems, TRIUMPH study | I5Q-MC-B004 | |
Phase 4 Pan-European prospective observational study of fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World: PEARL study | TV48125-MH-40146 | |
Phase 3 Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache | NCT04688775 | |
Phase 3 Multicenter, Open-Label 52-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine | NCT04686136 | |
Phase 3 Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants with Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE) | NCT04740827 | |
Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress) | NCT03855137 | |
Phase 4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder” | TEV-48125. NCT04041284 | |
Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache | NCT03971071 |
Luogo | Data | Congresso |
---|---|---|
Firenze | 2023 | Headache&CGRP |
Firenze | 2022 | Headache&CGRP |
Il centro ospita il past-president della SISC e due membri del centro studi SISC. |
Search for another Migraine Center:
List of Migraine Centers in Toscana List of Migraine Centers near Firenze
Subscribe our newsletter to receive our news and updates